person · Reporting owner

MARKISON BRIAN A

Disclosed activity across 5 companies

Tapewire entity: 82237
SEC CIK: 0001283061

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IMMUNOMEDICS INCIMMU · Entity 145732	Director	November 20, 2017	November 21, 2017
Lantheus Holdings, Inc.LNTH · Entity 690	Director · CEO	March 05, 2025	March 07, 2025
RVL Pharmaceuticals plcRVLP · Entity 108806	Director · Chief Executive Officer	August 08, 2022	August 09, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IMMUNOMEDICS INC

Report date November 20, 2017 · Filed November 21, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	90,788	Ending reported balance After 2017-11-20 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2017-11-20 · Exercise / conversion · Acquired 15,000 · Balance 99,178 Row 2 · 2017-11-20 · Sale · Disposed 8,390 · Balance 90,788 F1: The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $11.88 to $11.92. F2: The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2017-12-01	Direct	0	Reported balance After 2017-11-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-11-20 · Exercise / conversion · Disposed 15,000 · Balance 0

Filing footnotes · ownership attribution and instrument terms

F1: The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $11.88 to $11.92.

F2: The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.

Lantheus Holdings, Inc.

Report date March 05, 2025 · Filed March 07, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	232,420	Reported balance After 2025-03-05 transaction · row 1 1 source row Row 1 · 2025-03-05 · Grant · Acquired 70,909 · Balance 232,420 F1: Consists of 23,636 restricted stock units that vest in equal installments over a three-year period and 47,273 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award; however, the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.48 · Expires 2035-03-05	Direct	41,347	Reported balance After 2025-03-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-03-05 · Grant · Acquired 41,347 · Balance 41,347 F2: The option vests in three equal annual installments beginning on March 5, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of 23,636 restricted stock units that vest in equal installments over a three-year period and 47,273 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award; however, the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.

F2: The option vests in three equal annual installments beginning on March 5, 2026.

RVL Pharmaceuticals plc

Report date August 08, 2022 · Filed August 09, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	2,976,020	Reported balance After 2022-08-08 transaction · row 1 1 source row Row 1 · 2022-08-08 · Purchase · Acquired 850,000 · Balance 2,976,020

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALERE INC.

Report date October 03, 2017 · Filed October 03, 2017

Section 16 reporting ended · disclosed 2017-10-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-10-03 transaction · row 1 1 source row Row 1 · 2017-10-03 · Disposition to issuer · Disposed 5,530 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration").
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.73	Direct	0	Reported balance After 2017-10-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-10-03 · Disposition to issuer · Disposed 53,756 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration").

F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

Organogenesis Holdings Inc.

Report date December 10, 2018 · Filed December 12, 2018

Section 16 reporting ended · disclosed 2018-12-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary SharesSEC Table II · derivative / convertible security	Direct	133,589	Reported balance After 2018-12-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-12-10 · Disposition to issuer · Disposed 442,151 · Balance 133,589 F1: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2: 442,151 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date.

F2: 442,151 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 25, 2019 Filed Feb 27, 2019 17:32 UTC	RVL Pharmaceuticals plc OSMT · Entity 108806	GrantOrdinary Shares	387,991	$0.00	$0.00	Disclosure SEC source: 0001104659-19-011180 · a4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,876,233 F1 · kind: Represents a grant of restricted stock units. F1 · shares: Represents a grant of restricted stock units. Read SEC document
December 10, 2018 Filed Dec 12, 2018 21:45 UTC	Organogenesis Holdings Inc. ORGO · Entity 6275	Disposition to issuerClass B Ordinary Shares · Derivative	442,151	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-18-045055 · form4.xml · derivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,589 Underlying: Class A Ordinary Shares · 442,151 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2 · kind: 442,151 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination. F2 · price: 442,151 Class B ordinary shares were forfeited to the Issuer for no consideration prior to the closing of the Business Combination. F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of Avista Healthcare Public Acquisition Corp. (the "Issuer"), the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. Read SEC document
October 30, 2018 Filed Nov 1, 2018 18:25 UTC	Organogenesis Holdings Inc. AHPA · Entity 6275	OtherClass B Ordinary Shares · Derivative	5,510	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-065500 · a4.xml · derivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,740 Underlying: Class A Ordinary Shares · 5,510 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2 · kind: 5,510 Class B ordinary shares were transferred to Avista Acquisition Corp. for no consideration. F2 · price: 5,510 Class B ordinary shares were transferred to Avista Acquisition Corp. for no consideration. F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. Read SEC document
August 17, 2018 Filed Oct 15, 2018 20:56 UTC	Organogenesis Holdings Inc. AHPA · Entity 6275	Disposition to issuerClass B Ordinary Shares · Derivative	193,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-062195 · a4.xml · derivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 581,250 Underlying: Class A Ordinary Shares · 193,750 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2 · kind: 193,750 Class B ordinary shares were forfeited to the Issuer for no consideration. F2 · price: 193,750 Class B ordinary shares were forfeited to the Issuer for no consideration. F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. Read SEC document
March 05, 2018 Filed Mar 7, 2018 16:41 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantCommon Stock	7,911	$0.00	$0.00	Disclosure SEC source: 0000899243-18-006656 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,114 Read SEC document
November 20, 2017 Filed Nov 21, 2017 17:00 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	Exercise / conversionStock Options (right to buy) · Derivative	15,000	$0.00 Strike: $3.16	$0.00	Disclosure SEC source: 0001171843-17-007216 · form4markison.xml · derivative · entry 3 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 15,000 shares Expires 2017-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 20, 2017 Filed Nov 21, 2017 17:00 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	SaleCommon Stock	8,390	$11.89	$99,723.54	Disclosure SEC source: 0001171843-17-007216 · form4markison.xml · nonDerivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,788 F1 · price: The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $11.88 to $11.92. F2 · price: The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported. Read SEC document
November 20, 2017 Filed Nov 21, 2017 17:00 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	Exercise / conversionCommon Stock	15,000	$3.16	$47,400.00	Disclosure SEC source: 0001171843-17-007216 · form4markison.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:37 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	53,756	Not disclosed Strike: $33.73	Not disclosed	Disclosure SEC source: 0000950142-17-001790 · es1701014_4-markison.xml · derivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,756 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. Read SEC document
October 03, 2017 Filed Oct 3, 2017 17:37 UTC	ALERE INC. ALR · Entity 172772	Disposition to issuerCommon Stock	5,530	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-17-001790 · es1701014_4-markison.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration"). Read SEC document
August 11, 2017 Filed Aug 14, 2017 16:00 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantRestricted Stock Units · Derivative	7,051	$0.00	$0.00	Disclosure SEC source: 0001171843-17-005043 · f4_markison081417.xml · derivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,051 Underlying: Common Stock, par value $0.01 per share · 7,051 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Immunomedics, Inc. common stock. The restricted stock units shall vest upon the earlier of (i) the reporting person's completion of one year of service as a non-employee director from the date of grant, or (ii) the reporting person's continuation in service through the day immediately preceding the next annual stockholders meeting following the date of grant. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Immunomedics, Inc. common stock. The restricted stock units shall vest upon the earlier of (i) the reporting person's completion of one year of service as a non-employee director from the date of grant, or (ii) the reporting person's continuation in service through the day immediately preceding the next annual stockholders meeting following the date of grant. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Immunomedics, Inc. common stock. The restricted stock units shall vest upon the earlier of (i) the reporting person's completion of one year of service as a non-employee director from the date of grant, or (ii) the reporting person's continuation in service through the day immediately preceding the next annual stockholders meeting following the date of grant. Read SEC document
August 11, 2017 Filed Aug 14, 2017 16:00 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Options (right to buy) · Derivative	12,539	$0.00 Strike: $7.80	$0.00	Disclosure SEC source: 0001171843-17-005043 · f4_markison081417.xml · derivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,539 Underlying: Common Stock, par value $0.01 per share · 12,539 shares Expires 2024-08-11 Read SEC document
July 05, 2017 Filed Sep 28, 2017 17:15 UTC Amendment	Organogenesis Holdings Inc. AHPA · Entity 6275	PurchaseClass B Ordinary Shares · Derivative	186,320	$0.00	$558.96	Disclosure SEC source: 0001140361-17-036824 · form4.xml · derivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 Underlying: Class A Ordinary Shares · 186,320 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2 · date: The original Form 4 filed on July 7, 2017 is amended by this Form 4 amendment solely to correctly reflect the transaction date. No other changes have been made to the original Form 4. F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. Read SEC document
June 30, 2017 Filed Jul 5, 2017 21:13 UTC	ALERE INC. ALR · Entity 172772	Exercise / conversionRestricted Stock Units · Derivative	5,530	$0.00	$0.00	Disclosure SEC source: 0001179110-17-010143 · edgar.xml · derivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,530 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on June 30, 2017. F2 · derivative.expiration_date: The restricted stock units vested in full on June 30, 2017. Read SEC document
June 30, 2017 Filed Jul 5, 2017 21:13 UTC	ALERE INC. ALR · Entity 172772	Exercise / conversionCommon Stock	5,530	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-010143 · edgar.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. Read SEC document
February 27, 2017 Filed Mar 1, 2017 16:06 UTC	Lantheus Holdings, Inc. LNTH · Entity 690	GrantCommon Stock	8,730	$0.00	$0.00	Disclosure SEC source: 0000899243-17-005787 · doc4.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,203 Read SEC document
December 02, 2016 Filed Dec 7, 2016 21:00 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	Exercise / conversionRestricted Stock Units · Derivative	14,469	$0.00	$0.00	Disclosure SEC source: 0001171843-16-013545 · form4markinson.xml · derivative · entry 3 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 14,469 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Immunomedics, Inc. common stock. The restricted stock units shall vest upon the earlier of (i) the reporting person's completion of one year of service as a non-employee director from the date of grant, or (ii) the reporting person's continuation in service through the day immediately preceding the next annual stockholders meeting following the date of grant. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Immunomedics, Inc. common stock. The restricted stock units shall vest upon the earlier of (i) the reporting person's completion of one year of service as a non-employee director from the date of grant, or (ii) the reporting person's continuation in service through the day immediately preceding the next annual stockholders meeting following the date of grant. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Immunomedics, Inc. common stock. The restricted stock units shall vest upon the earlier of (i) the reporting person's completion of one year of service as a non-employee director from the date of grant, or (ii) the reporting person's continuation in service through the day immediately preceding the next annual stockholders meeting following the date of grant. Read SEC document
December 02, 2016 Filed Dec 7, 2016 21:00 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	Tax withholdingCommon Stock	5,737	Not disclosed	Not disclosed	Disclosure SEC source: 0001171843-16-013545 · form4markinson.xml · nonDerivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,178 F2 · price: The number of shares withheld to satisfy the tax withholding obligation of the reporting person upon vesting of Restricted Stock Units is correlated with the reporting person's tax withholding percentage based upon a price per share of $3.24. Read SEC document
December 02, 2016 Filed Dec 7, 2016 21:00 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	Exercise / conversionCommon Stock	14,469	Not disclosed	Not disclosed	Disclosure SEC source: 0001171843-16-013545 · form4markinson.xml · nonDerivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Delivery of common stock upon vesting of restricted stock units granted on December 2, 2015. Read SEC document
November 28, 2016 Filed Nov 29, 2016 16:39 UTC	Organogenesis Holdings Inc. AHPA · Entity 6275	PurchaseClass B Ordinary Shares · Derivative	161,180	$0.00	$483.54	Disclosure SEC source: 0001140361-16-088068 · form4.xml · derivative · entry 2 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,680 Underlying: Class A Ordinary Shares · 161,180 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. Read SEC document
November 28, 2016 Filed Jul 7, 2017 16:45 UTC	Organogenesis Holdings Inc. AHPA · Entity 6275	PurchaseClass B Ordinary Shares · Derivative	186,320	$0.00	$558.96	Disclosure SEC source: 0001140361-17-027466 · form4.xml · derivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 Underlying: Class A Ordinary Shares · 186,320 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. Read SEC document
November 25, 2016 Filed Nov 29, 2016 16:39 UTC	Organogenesis Holdings Inc. AHPA · Entity 6275	Disposition to issuerClass B Ordinary Shares · Derivative	43,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-16-088068 · form4.xml · derivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,500 Underlying: Class A Ordinary Shares · 43,750 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F2 · kind: 43,750 shares of the Class B Shares were forfeited to the Issuer at no cost in connection with the underwriters' election not to exercise the remaining unused portion of the over-allotment option, as described in the Issuer's registration statement on Form S-1 (File No. 333-213465). F2 · price: 43,750 shares of the Class B Shares were forfeited to the Issuer at no cost in connection with the underwriters' election not to exercise the remaining unused portion of the over-allotment option, as described in the Issuer's registration statement on Form S-1 (File No. 333-213465). F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association (the "Articles") of the Issuer, the Class B ordinary shares, par value $0.0001 per share (the "Class B Shares") will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's Business Combination, as defined in the Articles, on a one-for-one basis, subject to adjustment, and have no expiration date. Read SEC document
November 15, 2016 Filed Nov 17, 2016 17:55 UTC	ALERE INC. ALR · Entity 172772	GrantRestricted Stock Units · Derivative	5,530	$0.00	$0.00	Disclosure SEC source: 0001179110-16-031800 · edgar.xml · derivative · entry 1 MARKISON BRIAN A · CIK 0001283061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,530 Underlying: Common Stock · 5,530 shares Expires not disclosed F3 · security: All prior equity awards granted to the Reporting Person had vested in full on or prior to June 30, 2016. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. F2 · derivative.exercise_date: The restricted stock units will vest in full on June 30, 2017. F2 · derivative.expiration_date: The restricted stock units will vest in full on June 30, 2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.